A case series of subconjunctival triamcinolone acetonide injection for the treatment of upper eyelid retraction in thyroid eye disease
Nội dung chính của bài viết
Tóm tắt
This study aimed to descriptively assess changes in eyelid position, disease activity, and ocular surface parameters following subconjunctival triamcinolone acetonide (80 mg/2 mL) injection in patients with upper eyelid retraction associated with thyroid eye disease. A case series was conducted on patients treated at Hanoi Medical University Hospital from October 2024 to October 2025. A total of 10 patients and 13 eyes were analyzed; 70.0% of patients had unilateral involvement, while 30.0% presented with bilateral disease. All patients were in a euthyroid state and were maintained on Thyrozol 5-10 mg/day. The mean number of injections was 1.8 ± 0.79. The mean CAS decreased from 2.00 ± 0.89 to 1.36 ± 1.02, and the mean MRD1 decreased from 6.99 ± 1.92 mm to 4.32 ± 1.18 mm following treatment. Favorable clinical outcomes were achieved in 70.0% of patients, 20.0% demonstrated moderate improvement, and 10.0% did not reach the expected therapeutic response. Disease duration and pre-injection severity of eyelid retraction were associated with treatment outcomes. There was no complication reported, except for one case of subcutaneous drug deposition, which resolved spontaneously within one month of follow-up.
Chi tiết bài viết
Từ khóa
Thyroid eye disease, Graves’ ophthalmopathy, upper eyelid retraction, triamcinolone acetonide
Tài liệu tham khảo
2. Burch HB, Perros P, Bednarczuk T, et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022; 32(12): 1439-1470. doi:10.1089/thy.2022.0251.
3. Al-Badri WKW, Jellema HM, Potvin ARGG, van Nispen RMA, Bisschop PH, Saeed P. Psychological aspects of Graves’ ophthalmopathy. Endocr Connect. 2024; 13(9): e240259. doi:10.1530/EC-24-0259.
4. Gontarz-Nowak K, Szychlińska M, Matuszewski W, Stefanowicz-Rutkowska M, Bandurska-Stankiewicz E. Current Knowledge on Graves’ Orbitopathy. J Clin Med. 2020; 10(1): 16. doi:10.3390/jcm10010016.
5. Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N Engl J Med. 2009; 360(10): 994-1001. doi:10.1056/NEJMcp0806317.
6. Grisolia ABD, Couso RC, Matayoshi S, Douglas RS, Briceño CA. Non-surgical treatment for eyelid retraction in thyroid eye disease (TED). Br J Ophthalmol. 2018; 102(2): 158-163 doi:10.1136/bjophthalmol-2017-310695.
7. Lee SJ, Rim THT, Jang SY, et al. Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2013; 251(1): 261-270. doi:10.1007/s00417-012-2153-y.
8. Xu DD, Chen Y, Xu HY, Li H, Zhang ZH, Liu YH. Long-term effect of triamcinolone acetonide in the treatment of upper lid retraction with thyroid associated ophthalmopathy. Int J Ophthalmol. 2018; 11(8): 1290-1295. doi:10.18240/ijo.2018.08.07.
9. Hamed-Azzam S, Mukari A, Feldman I, Saliba W, Jabaly-Habib H, Briscoe D. Fornix triamcinolone injection for thyroid orbitopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2015; 253(5): 811-816. doi:10.1007/s00417-015-2957-7.
10. Xu D, Liu Y, Xu H, Li H. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Canadian Journal of Ophthalmology. 2012; 47(1): 34-41. doi:10.1016/j.jcjo.2011.12.005.
11. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021; 185(4): G43-G67. doi:10.1530/EJE-21-0479.